These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24290735)

  • 1. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
    Hagiwara M; Borker R; Oster G
    Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
    Borker R
    J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
    Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
    Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
    Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
    Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
    Ondrácková B; Demlová R; Komínek J
    Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
    De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
    PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
    Duh MS; Dial E; Choueiri TK; Fournier AA; Antras L; Rodermund D; Neary MP; Oh WK
    Curr Med Res Opin; 2009 Aug; 25(8):2081-90. PubMed ID: 19586325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and predicted cost of metastatic renal cell carcinoma in Finland.
    Purmonen T; Nuttunen P; Vuorinen R; Pyrhönen S; Kataja V; Kellokumpu-Lehtinen P
    Acta Oncol; 2010 Aug; 49(6):837-43. PubMed ID: 20331406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.
    Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason GAG; Heng D; Soulières D; Reaume MN; Basappa N; Lévesque E; Dragomir A
    Clin Drug Investig; 2018 Dec; 38(12):1155-1165. PubMed ID: 30267257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
    Choueiri TK; Duh MS; Clement J; Brick AJ; Rogers MJ; Kwabi C; Shah K; Percy AG; Antràs L; Jayawant SS; Chen K; Wang ST; Luka A; Neary MP; McDermott D; Oh WK
    BJU Int; 2010 May; 105(9):1247-54. PubMed ID: 19863525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
    Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
    Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
    Geynisman DM; Hu JC; Liu L; Tina Shih YC
    Clin Genitourin Cancer; 2015 Apr; 13(2):e93-100. PubMed ID: 25450038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
    Paz-Ares L; del Muro JG; Grande E; Díaz S
    J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
    Choueiri TK; McDermott D; Sheng Duh M; Sarda SP; Neary MP; Oh WK
    Urol Oncol; 2012; 30(6):848-55. PubMed ID: 20926319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
    Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
    Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
    Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
    Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.